Genevac-B Dosing Recommendations
Genevac-B (also marketed as Engerix-B) should be administered as 10 mcg (0.5 mL) for children birth through 19 years of age and 20 mcg (1.0 mL) for adults ≥20 years, given in a 3-dose series at 0,1, and 6 months. 1
Standard Dosing by Age Group
Infants and Children (Birth through 10 years)
- Dose: 10 mcg (0.5 mL)
- Schedule: 0,1,6 months
- Route: Intramuscular in anterolateral thigh (preferred in infants) 1
Adolescents (11-19 years)
- Dose: 10 mcg (0.5 mL)
- Schedule: 0,1,6 months
- Route: Intramuscular in deltoid 1
Adults (≥20 years)
- Dose: 20 mcg (1.0 mL)
- Schedule: 0,1,6 months
- Route: Intramuscular in deltoid 1
The 2022 ACIP guidelines confirm these dosing recommendations align with current universal hepatitis B vaccination recommendations for adults aged 19-59 years 2.
Special Populations
Hemodialysis Patients and Immunocompromised Adults (≥20 years)
- Dose: 40 mcg (2.0 mL) - given as two 20 mcg injections
- Schedule: 4 doses at 0,1,2, and 6 months
- Monitoring: Annual antibody testing recommended; give booster when anti-HBs falls below 10 mIU/mL 1
This higher dose and 4-dose schedule is critical because hemodialysis patients achieve lower antibody titers and lose protection more rapidly than healthy individuals 1.
Infants Born to HBsAg-Positive Mothers
- Dose: 10 mcg (0.5 mL)
- Schedule: 0,1,6 months (standard) OR 0,1,2,12 months (alternate)
- Critical: Must also receive HBIG in addition to vaccine 1
Alternate Schedules
Accelerated Schedule (for recent exposure or high-risk travel)
- Children/Adolescents: 10 mcg at 0,1,2,12 months
- Adults: 20 mcg at 0,1,2,12 months
- Rationale: Provides faster initial protection (99% seroprotected by month 3), with the 12-month dose ensuring prolonged maintenance 1
Extended Schedule (for low-risk populations)
- Ages 5-16 years: 10 mcg at 0,12,24 months
- Note: Only appropriate when extended schedule is acceptable based on low exposure risk 1
Administration Details
Route and Site
- Primary route: Intramuscular injection
- Infants <12 months: Anterolateral thigh (1-inch, 23-gauge needle)
- Toddlers/children ≤10 years: Deltoid (5/8-inch, 25-gauge needle)
- Older children/adults: Deltoid (1-inch, 23-gauge needle) 1
Critical Caveat - Avoid Gluteal Injection
Never administer in the gluteal region - this results in suboptimal immune response 1. This is a common error that significantly reduces vaccine efficacy.
Subcutaneous Administration
- Only for: Patients at risk of hemorrhage (e.g., hemophiliacs)
- Warning: Results in lower antibody titers and increased local reactions including subcutaneous nodules
- Use sparingly: Reserve for patients with true contraindication to IM injection 1
Interrupted Series Management
If the vaccination schedule is interrupted 1:
- Do not restart the series - simply continue where you left off
- After first dose delayed: Give second dose ASAP; separate doses 2 and 3 by ≥8 weeks
- After second dose delayed: Give third dose ASAP
- Minimum intervals:
- First to second dose: 4 weeks
- Second to third dose: 8 weeks
- First to third dose: 16 weeks
Doses given ≤4 days before minimum interval are considered valid.
Evidence Quality and Clinical Performance
Research data from India demonstrates that the 10 mcg dose of GeneVac-B produces excellent immunogenicity in adolescents (geometric mean titer 1373 mIU/mL one month after third dose, with 100% seroprotection maintained at 1 year) 3. In infants, GeneVac-B showed 98% seroconversion and 96% seroprotection rates, comparable to Engerix-B 4.
The vaccine has demonstrated excellent safety, with 98.73% of adverse events being non-serious, and 94.12% of reactions occurring within 3 days (primarily fever, local reactions, and rash) 5.
Preparation
- Shake well before withdrawal
- Inspect for particulate matter, discoloration, or cracks
- Should appear as slightly turbid white suspension
- Use as supplied - no dilution needed
- Discard any remaining vaccine in single-dose vial 1